Most Read Articles
Audrey Abella, 08 Aug 2018
Antioxidant supplementation did not improve semen parameters in oligoasthenoteratospermic men, or pregnancy rates in their partners, according to the MOXI* trial presented at ESHRE 2018.

Update on ADT: Degarelix shows promise in patients with advanced prostate cancer and CVD

26 Nov 2019
The incidence of prostate cancer (PC) and cardiovascular disease (CVD) typically increases with age; therefore, the choice of treatment for PC should take into account a patient’s underlying cardiovascular conditions. In this interview, Professor Laurence Klotz shared his take on androgen deprivation therapy (ADT) options for patients with prostate cancer who are at-risk of CV events.

Related MIMS Drugs

Editor's Recommendations
Most Read Articles
Audrey Abella, 08 Aug 2018
Antioxidant supplementation did not improve semen parameters in oligoasthenoteratospermic men, or pregnancy rates in their partners, according to the MOXI* trial presented at ESHRE 2018.